drug biospace - Robuta Search

https://www.biospace.com/fda/rezolute-lauds-unusual-fda-feedback-supportive-of-path-forward-for-hypoglycemia-drug Rezolute Lauds ‘Unusual’ FDA Feedback Supportive of Path Forward for Hypoglycemia Drug - BioSpace Mar 24, 2026 - While ersodetug missed the Phase 3 primary endpoint of a reduction in hypoglycemia events, Rezolute argued that this goal was confounded in part by behavioral... path forward drug biospace lauds fda feedback https://www.biospace.com/fda/biogen-bounces-back-with-fda-nod-for-high-dose-spinal-muscular-atrophy-drug Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug - BioSpace Mar 30, 2026 - The FDA rejected the high-dose regimen of Spinraza in September last year due to manufacturing concerns. spinal muscular atrophy bounces back fda nod high dose drug biospace https://www.biospace.com/deals/teva-bags-400m-backing-from-blackstone-to-advance-sanofi-partnered-drug Teva Bags $400M Backing From Blackstone To Advance Sanofi-Partnered Drug - BioSpace Mar 4, 2026 - The funding comes weeks after TL1A blocker duvakitug maintained clinical remission rates above 50% in patients with ulcerative colitis and Crohn’s disease in a... drug biospace teva bags 400m backing https://www.biospace.com/deals/takeda-breaks-up-with-denali-dumps-dementia-drug Takeda Breaks Up With Denali, Dumps Dementia Drug - BioSpace Apr 6, 2026 - Takeda and Denali Therapeutics first partnered in early 2018 to advance drugs for neurodegenerative diseases. One asset, for Alzheimer’s disease, was... drug biospace takeda breaks denali dumps https://www.biospace.com/business/opinion-the-high-stakes-tradeoffs-of-a-most-favored-nation-drug-policy The High Stakes Tradeoffs of a Most Favored Nation Drug Policy - BioSpace Aug 13, 2025 - President Donald Trump loves a deal, but Most Favored Nation drug pricing isn't a good one for anyone. favored nation drug high stakes tradeoffs policy biospace https://www.biospace.com/drug-development/kardigan-blood-pressure-drug-proves-hypothesis-despite-split-phase-2-readout Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout - BioSpace Mar 30, 2026 - While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting... blood pressure split phase kardigan drug proves https://www.biospace.com/fda/pharmas-hope-fda-precheck-can-help-avoid-facility-related-drug-rejections Pharmas Hope FDA PreCheck Can Help Avoid Facility-Related Drug Rejections - BioSpace Oct 28, 2025 - Executives from Eli Lilly, Merck and other companies foresee the FDA's new onshoring proposal being anything from a bureaucratic waste of time to a... help avoid related drug hope fda precheck https://www.biospace.com/fda/fda-ties-amgens-rare-inflammatory-disease-drug-to-eight-deaths-dozens-of-liver-injuries FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver Injuries - BioSpace Apr 1, 2026 - The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall risk-benefit profile. The pharma... inflammatory disease fda ties rare drug https://www.biospace.com/deals/merck-to-buy-terns-unprecedented-leukemia-drug-for-6-7b-as-keytruda-cliff-looms Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms - BioSpace Mar 25, 2026 - Merck’s acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Verona Pharma and Cidara Therapeutics, as the pharma prepares for... buy terns 6 7b merck leukemia drug https://www.biospace.com/drug-development/biogens-lupus-drug-reduces-disease-activity-further-de-risking-i-i-pipeline Biogen's Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline - BioSpace Mar 30, 2026 - William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another... disease activity pipeline biospace biogen lupus drug https://www.biospace.com/deals/neurocrine-nabs-rare-obesity-disorder-drug-in-surprising-2-9b-soleno-deal Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal - BioSpace Apr 6, 2026 - While an acquisition is a good exit for Soleno Therapeutics, the company’s acceptance of Neurocrine Biosciences’ $53-per-share offer came as a surprise to... 2 9b neurocrine nabs rare obesity https://www.biospace.com/drug-pricing Drug pricing - BioSpace drug pricing biospace https://www.biospace.com/drug-discovery Drug discovery - BioSpace drug discovery biospace https://www.biospace.com/drug-development/centessas-narcolepsy-drug-shows-compelling-effect-in-early-study Centessa’s Narcolepsy Drug Shows ‘Compelling’ Effect in Early Study - BioSpace Apr 7, 2025 - Analysts at BMO Capital Markets said Centessa’s orexin receptor agonist has “best-in-class” potential for narcolepsy, putting the company in a strong position... drug shows early study narcolepsy effect biospace https://www.biospace.com/drug-development/inside-the-race-to-build-the-next-generation-of-ai-drug-discovery-platforms Inside the Race to Build the Next Generation of AI Drug Discovery Platforms - BioSpace build next generation ai drug discovery inside race platforms https://www.biospace.com/job-trends/innovation-pressure-cooker-tackling-drug-discoverys-biggest-challenges Innovation Pressure Cooker: Tackling Drug Discovery’s Biggest Challenges - BioSpace Apr 2, 2026 - Drug discovery can be an uphill battle, especially lately given recent upheaval at the FDA and muted investment activity. BioSpace spoke to four industry... pressure cooker biggest challenges innovation tackling drug https://www.biospace.com/policy/trump-calls-on-congress-to-codify-most-favored-nation-drug-pricing-in-sotu Trump Calls on Congress To Codify Most Favored Nation Drug Pricing in SOTU - BioSpace Feb 25, 2026 - In his State of the Union address on Tuesday evening, President Donald Trump urged Republican leaders to pass legislation cementing his new drug pricing... favored nation drug trump calls congress codify pricing https://www.biospace.com/antibody-drug-conjugate-adc Antibody-drug conjugate (ADC) - BioSpace antibody drug conjugate adc biospace https://www.biospace.com/drug-delivery Drug Delivery News - BioSpace drug delivery news biospace https://www.biospace.com/drug-development/maze-loses-nearly-a-third-of-market-cap-on-mixed-midstage-kidney-drug-data Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data - BioSpace Mar 26, 2026 - Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung up” with the broad population data... loses nearly market cap drug data maze third https://www.biospace.com/business/trumps-mfn-pricing-expected-to-delay-more-european-drug-launches Trump’s MFN Pricing Expected To Delay More European Drug Launches - BioSpace Apr 1, 2026 - Following Insmed’s decision to hold off on launching a newly approved lung disease drug in Europe, experts anticipate more companies will do the same as they... european drug mfn pricing expected delay